Explore

Trendline Trendline
N-Power Medicine Secures $32M Series B Funding to Expand Community Oncology Research

N-Power Medicine Secures $32M Series B Funding to Expand Community Oncology Research

N-Power Medicine Secures $32M Series B Funding to Expand Community Oncology Research
Trendline Trendline
Roche Secures $1.5 Billion Oncology Partnership with Simcere Zaiming for B-Cell Disease Treatment

Roche Secures $1.5 Billion Oncology Partnership with Simcere Zaiming for B-Cell Disease Treatment

Roche Secures $1.5 Billion Oncology Partnership with Simcere Zaiming for B-Cell Disease Treatment
Rapid Read Rapid Read
CRISPR-Based Gene Therapy Shows Promise in Sustaining Lower Lipid Levels for a Year

CRISPR-Based Gene Therapy Shows Promise in Sustaining Lower Lipid Levels for a Year

Researchers have reported promising results from a small study involving a one-time CRISPR-based gene therapy shot that helped individuals with elevated cholesterol and triglyceride levels maintain significantly lower lipid levels for at least a year. Mel Mann, a patient advocate, highlighted this development, noting that the therapy represents a 'different model' compared to traditional treatments. The study, though small and involving severe cases, demonstrated that the highest dose of the CRISPR shot reduced LDL cholesterol and triglycerides by approximately half, with the effects sustained over the year. This suggests a potential for a durable therapeutic intervention for lipid management through gene editing.
Trendline Trendline
N-Power Medicine Secures $32M Series B Funding to Expand Oncology Research Network

N-Power Medicine Secures $32M Series B Funding to Expand Oncology Research Network

N-Power Medicine Secures $32M Series B Funding to Expand Oncology Research Network
Trendline Trendline
Aitia and Ono Pharmaceutical Partner to Advance Neurological Drug Discovery Using AI

Aitia and Ono Pharmaceutical Partner to Advance Neurological Drug Discovery Using AI

Aitia and Ono Pharmaceutical Partner to Advance Neurological Drug Discovery Using AI
Rapid Read Rapid Read
Fred Hutch Cancer Center Leads $15 Million National Clinical Trial for Older Adults with Acute Myeloid Leukemia

Fred Hutch Cancer Center Leads $15 Million National Clinical Trial for Older Adults with Acute Myeloid Leukemia

Fred Hutch Cancer Center is spearheading a new national clinical trial initiative, backed by a $15 million grant from the Patient-Centered Outcomes Research Institute (PCORI). This initiative aims to identify the most effective treatment strategies for older adults diagnosed with acute myeloid leukemia (AML), an aggressive and rapidly progressing blood cancer. The clinical trial program, led by Dr. Mohamed Sorror, will involve an 18-center U.S. consortium. It will compare stem cell transplantation with non-transplant therapies for AML patients after they achieve remission. This research is crucial given the challenges in treating AML in older populations. Additionally, Fred Hutch researchers, including Dr. Andrew C. Hsieh and Dr. Rashmi Mishra, have identified a molecular switch that allows prostate cancer to evade therapy, opening new avenues for treatment. Separately, Dr. David MacPherson and Dr. Gavin Ha received a $1.5 million grant to develop SCLCpheno-seq, a liquid biopsy for small cell lung cancer (...
Rapid Read Rapid Read
Aging Clocks Show Promise for Longevity Interventions but Face Reliability Challenges

Aging Clocks Show Promise for Longevity Interventions but Face Reliability Challenges

Aging clocks, developed using machine learning techniques on biological data, are designed to predict age-related conditions and mortality risk. These clocks utilize various data types, including omics data, clinical chemistry results from blood tests, and imaging data. When applied to individuals, a higher predicted age compared to chronological age often correlates with increased mortality risk and the presence of age-related conditions. The primary goal for these aging clocks is to provide a rapid assessment tool for novel longevity interventions, potentially eliminating the need for lengthy, decade-spanning clinical trials. However, a significant challenge remains: ensuring the reliability of these clocks in assessing the efficacy of new interventions. There is currently no direct, well-mapped connection between the data used to derive these clocks and the underlying mechanisms of aging, making it difficult to predict whether a given clock will accurately estimate the effects of a treatment without ext...
Rapid Read Rapid Read
ARPA-H Funds Teams to Advance On-Demand Genetic Medicine Manufacturing

ARPA-H Funds Teams to Advance On-Demand Genetic Medicine Manufacturing

The Advanced Research Projects Agency for Health (ARPA-H) has announced contract awards for its Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. This initiative aims to create an automated network capable of producing individualized, ribonucleic acid (RNA)-based genetic medicines on demand. The program seeks to replace the current slow, costly, and centralized manufacturing model with one designed for speed, scale, and reach. ARPA-H plans to invest up to $125 million in this research and development program. The goal is to develop automated manufacturing and real-time quality control into a distributed biomanufacturing network, allowing treatments to be made closer to the patient. This new paradigm is expected to empower communities nationwide to affordably produce cutting-edge treatments, rather than relying solely on major biomanufacturing hubs. The program will engage the U.S. Food and Drug Administration (FDA) to co-develop the necessary regulatory framework.
Trendline Trendline
Isomorphic Labs Secures $2.1 Billion Funding to Advance AI Drug Design

Isomorphic Labs Secures $2.1 Billion Funding to Advance AI Drug Design

Isomorphic Labs Secures $2.1 Billion Funding to Advance AI Drug Design
Rapid Read Rapid Read
Dr. Tobias Janowitz Appointed Director of Cancer Research at Feinstein Institutes, Northwell Health

Dr. Tobias Janowitz Appointed Director of Cancer Research at Feinstein Institutes, Northwell Health

Dr. Tobias Janowitz has been appointed as the new director of the Institute of Cancer Research at the Feinstein Institutes for Medical Research. In addition to this role, he will serve as the Robert and Janet Perro Professor in Cancer Research and director of Translational Cancer Research at Northwell Health's Cancer Institute. Dr. Janowitz will also continue to lead his established research program at Cold Spring Harbor Laboratory (CSHL) Cancer Center, fostering a closer strategic affiliation between CSHL and Northwell. His research, spanning over two decades, focuses on understanding the mechanisms driving cancer progression, particularly the metabolic, neuroendocrine, and immune circuits that influence disease progression and therapeutic response. He has investigated how systemic stress induced by tumors alters energy metabolism, elevates stress hormones, and weakens the immune system, contributing to cancer cachexia, a severe wasting syndrome. As a gastrointestinal oncologist, Dr. Janowitz aims to rede...
Trendline Trendline
Digital Twins Revolutionize Drug Development by Enhancing Simulation and Predictive Capabilities

Digital Twins Revolutionize Drug Development by Enhancing Simulation and Predictive Capabilities

Digital Twins Revolutionize Drug Development by Enhancing Simulation and Predictive Capabilities
Rapid Read Rapid Read
IU Health Launches Theranostics Center of Excellence to Expand Personalized Cancer Treatments

IU Health Launches Theranostics Center of Excellence to Expand Personalized Cancer Treatments

Indiana University Health has announced the establishment of the IU Health Theranostics Center of Excellence, a new program designed to provide highly personalized cancer treatment. This initiative integrates advanced medical imaging, precision diagnostics, and image-targeted therapies. The program aims to improve patient outcomes by accelerating access to precision medicine across Indiana. It builds upon existing strengths within IU Health and the IU School of Medicine, leveraging their expertise in precision genomics and clinical trial infrastructure. The center will initially focus on FDA-approved precision-targeted therapies for prostate and neuroendocrine cancers, with plans to expand access to investigational treatments for other cancer types. The launch was made possible by a $20 million gift commitment from Sarah and John Lechleiter and Deborah and Randall Tobias, which was matched by IU Health, bringing the total investment to $40 million. This funding established the Tobias-Lechleiter Institute f...